Description
TCR-based T cell immunotherapy for AML: Multidimensional aids in optimising treatment and patient identification
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: TCR-based T cell immunotherapy for AML: Multidimensional aids in optimising treatment and patient identification
€3.03
